| Identification | Back Directory | [Name]
N-[3-[4,5-Dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxo-2-pyrazinyl]-2-methylphenyl]-4-(tert-butyl)benzamide | [CAS]
910232-84-7 | [Synonyms]
GCI1746
CGI-1746
CGI-1746/CGI1746
N-[3-[4,5-Dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxo-2-pyrazinyl]-2-met
4-tert-butyl-N-(2-methyl-3-(4-methyl-6-(4-(morpholine-4-carbonyl)phenylamino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide
N-[3-[4,5-Dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxo-2-pyrazinyl]-2-methylphenyl]-4-(tert-butyl)benzamide
N-[3-[4,5-dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxopyrazinyl]-2-methylphenyl]-4-(1,1-dimethylethyl)-benzamide
N-[3-[4,5-Dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxo-2-pyrazinyl]-2-methylphenyl]-4-(tert-butyl)benzamide CGI-1746 | [Molecular Formula]
C34H37N5O4 | [MDL Number]
MFCD18782602 | [MOL File]
910232-84-7.mol | [Molecular Weight]
579.71 |
| Chemical Properties | Back Directory | [density ]
1.22 | [storage temp. ]
Store at -20°C | [solubility ]
≥29 mg/mL in DMSO; insoluble in H2O; ≥6.72 mg/mL in EtOH with gentle warming and ultrasonic | [form ]
solid | [color ]
White to light yellow |
| Questions And Answer | Back Directory | [Description]
CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM. | [In vitro]
CGI1746 is specific for Btk, with ～1,000-fold selectivity over Tec and Src family kinases. In an ATP-free competition binding assay, the dissociation constant for Btk is 1.5 nM. CGI1746 inhibits Btk activity in a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. CGI1746 inhibits both auto-and transphosphorylation steps necessary for enzyme activation. CGI1746 completely inhibits anti-IgM–induced murine and human B cell proliferation, with IC50s of 134 nM and 42 nM, respectively, but had no effect on anti-CD3-and anti-CD28–induced T cell proliferation. CGI1746 potently inhibits the proliferation of CD27+IgG+ B cells isolated from the tonsils of four human donors with an average IC50 of 112 nM. In macrophages, CGI1746 abolishes FcγRIII-induced TNFα, IL-1β and IL-6 production. CGI1746 potently inhibits TNFα, IL-1β and, to a lesser extent, IL-6 (three-to eight-fold higher IC50) production in human monocytes stimulated with immobilized or soluble immune complexes. | [In vivo]
CGI1746 abrogates B cell–dependent arthritis. CGI1746 treatment (100 mg/kg, s.c, twice-daily dosing) results in significant inhibition (97%) of overall clinical arthritis scores. CGI1746 treatment substantially reduces TNFα, IL-1β and IL-6, as well as MCP1 and MIP-1α on both the mRNA and protein level in the passive anti-collagen II antibody–induced arthritis (CAIA) model. CGI1746 shows comparable efficacy to TNFα blockade and significantly reduces clinical scores, as well as joint inflammation, in mice or rats with established arthritis. |
| Hazard Information | Back Directory | [Uses]
CGI 1746 is a Bruton’s tyrosine kinase (Btk) inhibitor to be used in antitumor drugs. | [target]
Btk | [storage]
Store at -20°C | [References]
[1] JULIE A DI PAOLO. Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis[J]. Nature chemical biology, 2010, 7 1: 41-50. DOI: 10.1038/nchembio.481
[2] AKINTUNDE AKINLEYE. Ibrutinib and novel BTK inhibitors in clinical development.[J]. Bioconjugate Chemistry Bioconjugate, 2013: 59. DOI: 10.1186/1756-8722-6-59 |
|
| Company Name: |
D&C Chemicals
|
| Telephone: |
+86-21-58447131 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList16963/0_EN.htm |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|